Abstract:Two new complexes of Pd( II ), [Pd(L1)Cl]Cl ( Pd1 ) and [Pd(L2)Cl]Cl ( Pd2 ), (where L1 = N 2 , N 6 -bis(5-methylthiazol-2-yl)pyridine-2,6-dicarboxamide and L2 = N 2 , N 6 -di(benzo[ d ]thiazol-2-yl)pyridine-2.6-dicarboxamide) were synthesized. Characterization of the complexes was performed using elemental analysis, IR, 1 H NMR spectroscopy and MALDI-TOF mass spectrometry. The nucleophilic substitution reactions of complexes with L -Methionine ( L -Met), L -Cysteine ( L -Cys) and guanosine-5′-monophosphate (5′-GMP) were studied by stopped-flow method at physiological conditions (pH = 7.2 and 37 °C). Complex Pd1 was more reactive than Pd2 in all studied reactions, while the order of reactivity of the selected ligands was: L -Met > L -Cys > 5′-GMP. The interaction of complexes with calf thymus-DNA (CT-DNA) was studied by Uv–Vis absorption and fluorescence emission spectroscopy. Competitive binding studies with intercalative agent ethidium bromide (EB) and minor groove binder Hoechst 33258 were performed as well. Both complexes interacted with DNA through intercalation and minor groove binding, where the latter was preferred. Additionally, the interaction of Pd1 and Pd2 complexes with human serum albumin (HSA) was studied employing fluorescence quenching spectroscopy. The results indicate a moderate binding affinity of complexes, with slightly stronger binding of the Pd1 . Fluorescence competition experiments with site-markers (eosin Y and ibuprofen) for HSA were used to locate the binding site of Pd1 to the HSA. Additionally, the interaction with DNA and HSA was studied by molecular docking and the revealed results were in good agreement with the experimentally obtained ones. Pd1 complex exhibited cytotoxicity toward human (HCT116) and mouse cell lines (CT26) of colorectal cancer, mouse (4T1) and human (MDA-MB468) breast cancer lines and non-cancerous mouse mesenchymal stem cells (mMSC). In addition, Pd1 complex demonstrated significant selectivity towards cancer cells over non-cancerous mMSC, indicating a high potential to eliminate malignant cells without affecting normal cells. It induced apoptosis in CT26 cells, effectively arrested the cell cycle in the S phase, and selectively down-regulated cyclin D and cyclin E. Moreover, it can alter the expression of cell cycle regulators by increasing p21 and decreasing p-AKT. These findings confirm its ability to disrupt key tumor cell survival signals and suggest that the Pd1 complex is a potent candidate for effective cancer treatment.

Potent saccharinate-containing palladium(II) complexes for sensitization to cancer therapy

Pd(II) and Pt(II) saccharinate complexes with two phosphine derivatives: Synthesis, anticancer and antiangiogenic activities

Endowing Pt(IV) with Perfluorocarbon Chains and Human Serum Albumin Encapsulation for Highly Effective Antitumor Chemoimmunotherapy.

Pd(ii) complexes bearing NNS pincer ligands: unveiling potent cytotoxicity against breast and pancreatic cancer

Palladium(II) Complexes with N,N′-Dialkyl-1,10-phenanthroline-2,9-dimathanamine: Synthesis, Characterization and Cytotoxic Activity

Two novel SNS-donor palladium(II) complexes of benzoxazole and benzothiazole derivatives as potential anticancer agentsPlease do not adjust margins

The cytotoxicity of palladium (II) complexes containing 1,2‐ or 1,4‐diazine bridging ligands on squamous cell carcinoma cells in vitro: Insights in the mechanisms of action

A Nanomedicine Based on Stoichiometric Coordination of Camptothecin and Organoplatinum (II) for Synergistic Antitumor Therapy.

Mixed N‐heterocyclic carbene and benzyl‐, phenethyl‐, and biphenylamine coordinated Pd complexes: Anticancer activities and stereo‐electronic effects

Synthesis, characterization and anticancer properties: A series of highly selective palladium(II) substituted-terpyridine complexes

Pd(II)/diphosphine/curcumin complexes as potential anticancer agents

Anticancer behaviour of 2,2′-(pyridin-2-ylmethylene)bis(5,5-dimethylcyclohexane-1,3-dione)-based palladium(II) complex and its DNA, BSA binding propensity and DFT study

Cationic first-row transition metal saccharinate complexes with tris(2-pyridylmethyl)amine: Synthesis, structures and anticancer studies

Design, Synthesis and Biological Evaluation of a Novel Platinum(ii) Complex Possessing Bioreductive Groups for Cancer Therapy

Potent cyclometallated Pd(II) antitumor complexes bearing α-amino acids: synthesis, structural characterization, DNA/BSA binding, cytotoxicity and molecular dynamics simulation

New Pd(ii)-pincer type complexes as potential antitumor drugs: synthesis, nucleophilic substitution reactions, DNA/HSA interaction, molecular docking study and cytotoxic activity

Palladium(II)‐Imidoyl Complexes: A New Piece in the Puzzle of Organopalladium Anticancer Agents

Synthesis and anticancer activities of novel Pt (II) and Pd (II) complexes with 4‐(2,2′:6′,2′′‐terpyridin‐4′‐yl)phenol as ligand

Synthesis, characterisation, and anticancer and antioxidant activities of novel complexes of palladium and an organic Schiff-base ligand

Supramolecular palladium complexes based on guanidinium pillar[5]arene for cancer therapy

Palladium complexes with terpene derivatives of ethylenediamine and benzylamine: Synthesis and study of antitumor properties